

Atty. Dkt. No. ABI1460-3
(071243-1317)**In the Claims:**

Please replace [✓]claims 1, 9, 17, 18, 25 and 29-30 with the re-written forms thereof presented herewith. For the Examiner's convenience, a complete set of the pending claims is provided, with each claim labeled as appropriate as "Currently amended" or "Original".

- A¹
1. (Currently amended) A method for treating hyperplasia in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising drug and coated with a protein.
 2. (Original) A method according to claim 1 wherein said drug is in nanoparticle form and is dispersed in said protein.
 3. (Original) A method according to claim 1 wherein said hyperplasia occurs in blood vessel neointima.
 4. (Original) A method according to claim 1 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.
 5. (Original) A method according to claim 4 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.
 6. (Original) A method according to claim 1 wherein said composition is administered systemically.
 7. (Original) A method according to claim 6 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.
 8. (Original) A method according to claim 1 wherein said composition is administered before, during or after the occurrence of said hyperplasia.

Atty. Dkt. N . ABI1460-3
(071243-1317)

A²

9. (Currently amended) A method for reducing neointimal hyperplasia associated with vascular interventional procedure(s) in a subject in need thereof, said method comprising administering to said subject an effective amount of a composition comprising at least one drug ~~and~~ coated with a protein.

10. (Original) A method according to claim 9 wherein said procedure comprises angioplasty, stenting or atherectomy.

11. (Original) A method according to claim 9 wherein said composition is administered before, during or after the vascular interventional procedure.

12. (Original) A method according to claim 9 wherein said composition is administered at the time of the vascular interventional procedure.

13. (Original) A method according to claim 9 wherein said effective amount falls in the range of about 0.01 mg/kg up to about 15 mg/kg for a human subject.

14. (Original) A method according to claim 13 wherein said administration of said composition is repeated over a dosing cycle between 1 day and 6 months.

15. (Original) A method according to claim 9 wherein said composition is administered systemically.

16. (Original) A method according to claim 9 wherein said composition is administered by deployment of a stent containing said at least one drug coated thereon.

A³

17. (Currently amended) A method to reduce proliferation and cell migration in a subject undergoing a vascular interventional procedure, said method comprising systemically administering a formulation comprising a drug that inhibits proliferation and

Atty. Dkt. No. ABI1460-3
(071243-1317)

A³
con. cell migration, and a biocompatible protein to said subject before, during or after said procedure, wherein said drug is coated with said protein.

18. (Currently amended) A composition [for treatment of hyperplasia] said composition comprising at least one drug and coated with a protein.

19. (Original) A composition according to claim 18 wherein said at least one drug is in nanoparticle form and is dispersed in said protein.

20. (Original) A composition according to claim 18 wherein said hyperplasia occurs in blood vessel neointima.

21. (Original) A composition according to claim 18 wherein said drug is a taxane or analog or homolog thereof, an epothilone or analog or homolog thereof, or a rapamycin or analog or homolog thereof.

22. (Original) A composition according to claim 21 wherein said taxane is paclitaxel.

23. (Original) A composition according to claim 18 wherein said composition is suitable for systemic administration.

24. (Original) A composition according to claim 23 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

A⁴
25. (Currently amended) A composition for reducing neointimal hyperplasia associated with vascular interventional procedure(s), said composition comprising at least one drug and coated with a protein.

Atty. Dkt. No. ABI1460-3
(071243-1317)

26. (Original) A composition according to claim 25 wherein said procedure is angioplasty, stenting or atherectomy.

27. (Original) A composition according to claim 25 wherein said composition is suitable for systemic administration.

28. (Original) A composition according to claim 27 wherein administration is accomplished intra-arterially, intravenously, by inhalation, or orally.

A5 29. (Currently amended) A method to reduce the toxicity of a drug that inhibits proliferation and migration of cells, said method comprising combining said drug with a biocompatible protein, wherein said drug is coated with said protein.

30. (Currently amended) A pharmaceutical formulation with reduced toxicity, said formulation comprising a drug that inhibits proliferation and cell migration, and coated with a biocompatible protein.